Page 10 - Presentation

DDR variants are significantly more prevalent in metastatic prostate

cancer than in localized disease

Prevalence of DDR variants in published studies of localized and advanced prostate cancer

14 13.3%

12 Advanced
Localized

10
Prevalence (%) 8 7.3% 6.9% 6%

6

4 3% 4% 3%
2.7%
1.9% 1.9% 2% 2%
2 1% 1.3% 1.2% 1.4%
0.4% 0.4% 0.7% 0.6%
0% NR 0.14% 0%
0
BRCA2 BRCA1 ATM CHEK2 CDK12 PALB2 RAD51C RAD51D FANCD2 MLH1 MSH2 MSH6

Gene

DDR variants are significantly more prevalent in metastatic (27%) than in localized (10%) prostate cancer 1,2

DDR, DNA damage response
ATM, ATM serine/threonine kinase; BRCA1, Breast Cancer 1; BRCA2, Breast Cancer 2; CHEK2, Checkpoint kinase 2; CDK12, Cyclin-dependent kinase 12; PALB2, Partner and localizer of BRCA2; RAD51C,
RAD51 Paralog C; RAD51D, RAD51 Paralog D; FANCD2, , Fanconi anemia, complementation group D2; MLH1, mutL homolog 1; MSH2, mutS homolog 2; MSH6, mutS homolog 6.
1. Lozano R et al. Br J Cancer 2021;124:552–63; 2. Armenia J et al. Nature Genet 2018;50:645–51.